Latest news
Pfizer Options Spot-On: On August 7th, 172.02K Contracts Were Traded, With 2.63 Million Open Interest - MoomooMoomoo · Sat, 08 Aug 2026 02:48:50 GMTGuggenheim Adjusts Price Target on Pfizer to $31 From $35, Maintains Buy Rating - MoomooMoomoo · Fri, 07 Aug 2026 10:45:52 GMTPfizer Options Spot-On: On August 5th, 88,978 Contracts Were Traded, With 2.57 Million Open Interest - MoomooMoomoo · Wed, 05 Aug 2026 20:59:11 GMTA Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $26 to $34 - MoomooMoomoo · Wed, 05 Aug 2026 18:22:29 GMTRothschild & Co Redburn Adjusts Pfizer Price Target to $25 From $24, Maintains Neutral Rating - MoomooMoomoo · Wed, 05 Aug 2026 15:37:56 GMTPfizer Logs Mixed 2Q on Oncology Growth, Covid-19 Declines - MoomooMoomoo · Tue, 04 Aug 2026 13:17:47 GMTPfizer (PFE.US) sees reduced earnings pressure: Strong demand for its legacy drug portfolio in Q2 drives an upward revision of its 2026 revenue guidance, alongside an additional $2.5 billion in cost reductions. - MoomooMoomoo · Tue, 04 Aug 2026 12:52:06 GMTPfizer Q2 Adjusted Earnings Decline, Revenue Increases; 2026 Revenue Outlook Narrowed - MoomooMoomoo · Tue, 04 Aug 2026 12:28:28 GMT